NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Inc. (NASDAQ:CYTK) announced its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.06. The biopharmaceutical company earned $6.06 million during the quarter, compared to the consensus estimate of $7.80 million. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 378.70%. View Cytokinetics' Earnings History.

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Cytokinetics.

6 equities research analysts have issued 1 year target prices for Cytokinetics' shares. Their forecasts range from $16.00 to $26.00. On average, they expect Cytokinetics' stock price to reach $21.50 in the next year. This suggests a possible upside of 126.1% from the stock's current price. View Analyst Price Targets for Cytokinetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

News coverage about CYTK stock has trended positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Cytokinetics.

Some companies that are related to Cytokinetics include Ra Pharmaceuticals (RARX), Synthorx (THOR), Portola Pharmaceuticals (PTLA), Zogenix (ZGNX), Tricida (TCDA), Insmed (INSM), Cambrex (CBM), Ironwood Pharmaceuticals (IRWD), Pacira Biosciences (PCRX), Prestige Consumer Healthcare (PBH), Aimmune Therapeutics (AIMT), Ligand Pharmaceuticals (LGND), Turning Point Therapeutics (TPTX), Dicerna Pharmaceuticals (DRNA) and ChemoCentryx (CCXI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (amgn), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Geron (GERN), TG Therapeutics (TGTX) and Inovio Pharmaceuticals (INO).

Cytokinetics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.93%), Point72 Asset Management L.P. (0.73%), Rhumbline Advisers (0.28%), Chicago Equity Partners LLC (0.25%), Squarepoint Ops LLC (0.20%) and Barclays PLC (0.19%). Company insiders that own Cytokinetics stock include Caryn Gordon Mcdowell, Fady Ibraham Malik and Robert I Blum. View Institutional Ownership Trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., State Street Corp, Public Employees Retirement System of Ohio and Meeder Asset Management Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC, Assenagon Asset Management S.A., Squarepoint Ops LLC, Barclays PLC, State of Alaska Department of Revenue, Voloridge Investment Management LLC, SG Americas Securities LLC and California Public Employees Retirement System. View Insider Buying and Selling for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $9.51.

Cytokinetics has a market capitalization of $561.87 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]